Screens in Childhood: effects on sleep, learning and attention. Principles for healthy uses

Mgr. Michaela Slussareff, Ph.D.

Psychiatr. praxi 2019; 20(2e)  

The article focuses on the most important topics within the issue of healthy usage of technology in children: 1. blue light and its impact on childhoodsleep, 2. the use of screens to accelerate cognitive development, and 3. the early screen exposure and later development of ADD/ADHD. With regardto the critical milestones of cognitive development, we discuss the most risky group, i.e. children aged 0 to 6 years. The text summarizes the mainfindings from current foreign and domestic research, and is accompanied by the basic guidelines of technology use in toddlers and preschool children.

Recurrent isolated sleep paralysis

MUDr. Jitka Bušková, Ph.D., Mgr. Monika Kliková

Psychiatr. praxi 2019; 20(2e)  

Isolated sleep paralysis occurs in up to 7,6 % of general population, which makes it to be a common sleep disorder. Recurrent isolated sleepparalysis (RISP) means REM (rapid eye movement) related parasomnia, which occurs recurrently during the transition between sleep and wakethat means during falling asleep or awakening. It is a transient loss of speech and voluntary movement that affects limbs and trunk muscles,which is especially at the beginning of the accompanied by an intensive fear. This burdensome experience can be elevated by accompanyingfearful dreamy delusions, so called hypnagogic/hypnopompic hallucinations. Pathophysiological...

Antiparkinsonian drugs, mental disorders in patients with Parkinson’s disease and drug-drug interactions

Michal Prokeš, Josef Suchopár

Psychiatr. praxi 2019; 20(2e)  

Patients with Parkinson´s disease (PN), a common neurodegenerative disorder, suffer not only from movement disorder, but also from mental disorders including behavioral disorders and psychosis. These disorders are closely related to dopaminergic treatment of PN. Despite knowledge of the clinical features of these disorders, many patients may not be diagnosed in time. Another issue are drug-drug interactions, because patients with PN are treated for associated diseases usually by other physicians, who may not always be aware, that the antiparkinsonian or antipsychotic drugs interact with other commonly prescribed drugs. This article introduces the medical...

E-verze 2/19

Psychiatr. praxi 2019; 20(2e)